Unapproved ‘Wolverine’ Peptide Gains Popularity Amid Regulatory Uncertainty

Rising use of unapproved BPC-157 peptide linked to RFK Jr sparks concerns over safety and efficacy.

September 17, 2026 One Min Read

POLICY WIRE — City, Country — An unapproved peptide compound known as BPC-157 is gaining traction among consumers despite a lack of regulatory approval and limited scientific evidence on its safety and effectiveness.

The compound, which has been promoted online for pain relief, recovery, and athletic performance, has seen increased usage driven by social media and endorsements from U.S. Health Secretary Robert F. Kennedy Jr., who recently supported its compounding by pharmacies.

📄 POLICY WIRE WHITEPAPER PUBLISHED: PAKISTAN’S NATIONAL SECURITY POLICY PRIORITIES

👉 READ BY CLICKING HERE

BPC-157 is often combined with another peptide called TB-500 in what is referred to as the “Wolverine stack.” Although it has not received formal approval in the U.S., it has found a growing audience in the gray market. Market analysts predict the peptides could become a $2 billion to $3 billion industry if they gain regulatory legitimacy.

Reporting by Policy-Wire (PW)

Author

Editorial Desk

Policy Wire is your go-to editorial hub for insightful perspectives and informed analysis on pressing policy issues, both regionally and globally. Over the years, Policy Wire has collaborated with leading international news agencies—including AFP, AP, Reuters, and others—to provide fact-based reporting and nuanced commentary. With a commitment to clarity and credibility, we aim to bridge the gap between complex policy debates and public understanding, ensuring that our readers stay informed on the issues shaping the world today.